Yuee Teng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yuee Teng has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Chen-Yang Zhao
Central Laboratory, The Fourth Hospital of China Medical University, Shenyang, Liaoning 110032, P.R. China
1 shared publicationChun-Lei Zheng
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
1 shared publicationJing Shi
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
1 shared publicationKe-Zuo Hou
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
1 shared publicationKezuo Hou
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
1 shared publicationLingyun Zhang
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
1 shared publication
Latest Publications
- 2 August 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (4) , 3265-3272
FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells
Trastuzumab has been widely applied as a treatment for human epidermal growth factor 2 (HER2)‑ overexpressing breast cancer. However, the therapeutic efficacy of trastuzumab is limited. Flap endonuclease 1 (FEN1) is a multifunctional endonuclease that has a crucial role in DNA recombination and repair. Inhibition of FEN1 is associated with the reversal of anticancer drug resistance. However, it is unclear whether FEN1 is involved in trastuzumab resistance. In the present study, it was demonstrated that trastuzumab increases the expression of FEN1, and FEN1 knockdown significantly enhanced the sensitivity of BT474 cells to trastuzumab (P<0.05). It was also revealed that trastuzumab induced HER receptor activation, increased binding with FEN1 and estrogen receptor α (ERα), and upregulated ERα‑target gene transcription (P<0.05). Upon silencing of FEN1 expression with siRNA, activation of HER receptor and FEN1 binding to ERα were decreased, and trastuzumab‑induced ERα target gene upregulation was partially ameliorated (P<0.05). These results suggest that FEN1 may mediate trastuzumab resistance via inducing HER receptor activation and enhancing ERα‑target gene transcription. The findings of the present study indicate a novel role of FEN1 in trastuzumab resistance, suggesting that targeting FEN1 may enhance the efficiency of trastuzumab as a treatment for HER2‑positive breast cancer.
- 2 August 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (4) , 3265-3272
FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells
Trastuzumab has been widely applied as a treatment for human epidermal growth factor 2 (HER2)‑ overexpressing breast cancer. However, the therapeutic efficacy of trastuzumab is limited. Flap endonuclease 1 (FEN1) is a multifunctional endonuclease that has a crucial role in DNA recombination and repair. Inhibition of FEN1 is associated with the reversal of anticancer drug resistance. However, it is unclear whether FEN1 is involved in trastuzumab resistance. In the present study, it was demonstrated that trastuzumab increases the expression of FEN1, and FEN1 knockdown significantly enhanced the sensitivity of BT474 cells to trastuzumab (P<0.05). It was also revealed that trastuzumab induced HER receptor activation, increased binding with FEN1 and estrogen receptor α (ERα), and upregulated ERα‑target gene transcription (P<0.05). Upon silencing of FEN1 expression with siRNA, activation of HER receptor and FEN1 binding to ERα were decreased, and trastuzumab‑induced ERα target gene upregulation was partially ameliorated (P<0.05). These results suggest that FEN1 may mediate trastuzumab resistance via inducing HER receptor activation and enhancing ERα‑target gene transcription. The findings of the present study indicate a novel role of FEN1 in trastuzumab resistance, suggesting that targeting FEN1 may enhance the efficiency of trastuzumab as a treatment for HER2‑positive breast cancer.
- Open Access
- 16 February 2015
- Published by Spandidos Publications in Oncology Letters
- Vol. 9 (4) , 1707-1714
Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy
The expression of phosphorylated Akt (pAkt) and phosphorylated extracellular‑regulated kinase 1/2 (pErk1/2) proteins may result in breast cancer progression and drug resistance in vitro, however, compelling evidence regarding the clinical significance of pAkt and pErk1/2 in early‑stage breast cancer is currently lacking. Thus, the aim of the present study was to determine the prognostic value of pAkt and pErk1/2 expression in early‑stage breast cancer patients treated with anthracycline‑based adjuvant chemotherapy. Tumor specimens were obtained from 256 patients with early‑stage breast cancer who had been treated with anthracycline‑based adjuvant chemotherapy, and pAkt and pErk1/2 protein expression was immunohistochemically determined. The interactions between pAkt, pErk1/2 and clinical characteristics were assessed by performing χ2 tests, and survival functions were estimated using the Kaplan‑Meier method. It was identified that pAkt and pErk1/2 were expressed in 38.7 and 33.6% of patients, respectively, and that pAkt protein expression was correlated with pErk1/2 protein expression (P<0.001). In addition, after a median follow‑up period of 52.5 months, the patients with pAkt‑ and pErk1/2‑negative tumors experienced a significantly longer disease‑free survival (DFS) time compared with pAkt‑ or pErk1/2‑positive patients (P=0.028). pErk1/2 expression was associated with the decreased DFS time of the patients (P=0.049), and pAkt and pErk1/2 expression were associated with the decreased DFS time in human epidermal growth factor receptor (HER2)‑positive patients (P=0.002). pErk1/2 expression was associated with chemotherapy resistance (P=0.016). Thus, the coexpression of pAkt and pErk1/2 was an independent factor for a poor prognosis in early‑stage and HER2‑positive breast cancer patients. By contrast, pErk1/2 expression alone may be a poor predictor for determining the efficacy of anthracycline‑based chemotherapy.
- 16 February 2015
- Published by Spandidos Publications in Oncology Letters
- Vol. 9 (4) , 1707-1714
Open AccessClinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy
The expression of phosphorylated Akt (pAkt) and phosphorylated extracellular‑regulated kinase 1/2 (pErk1/2) proteins may result in breast cancer progression and drug resistance in vitro, however, compelling evidence regarding the clinical significance of pAkt and pErk1/2 in early‑stage breast cancer is currently lacking. Thus, the aim of the present study was to determine the prognostic value of pAkt and pErk1/2 expression in early‑stage breast cancer patients treated with anthracycline‑based adjuvant chemotherapy. Tumor specimens were obtained from 256 patients with early‑stage breast cancer who had been treated with anthracycline‑based adjuvant chemotherapy, and pAkt and pErk1/2 protein expression was immunohistochemically determined. The interactions between pAkt, pErk1/2 and clinical characteristics were assessed by performing χ2 tests, and survival functions were estimated using the Kaplan‑Meier method. It was identified that pAkt and pErk1/2 were expressed in 38.7 and 33.6% of patients, respectively, and that pAkt protein expression was correlated with pErk1/2 protein expression (P<0.001). In addition, after a median follow‑up period of 52.5 months, the patients with pAkt‑ and pErk1/2‑negative tumors experienced a significantly longer disease‑free survival (DFS) time compared with pAkt‑ or pErk1/2‑positive patients (P=0.028). pErk1/2 expression was associated with the decreased DFS time of the patients (P=0.049), and pAkt and pErk1/2 expression were associated with the decreased DFS time in human epidermal growth factor receptor (HER2)‑positive patients (P=0.002). pErk1/2 expression was associated with chemotherapy resistance (P=0.016). Thus, the coexpression of pAkt and pErk1/2 was an independent factor for a poor prognosis in early‑stage and HER2‑positive breast cancer patients. By contrast, pErk1/2 expression alone may be a poor predictor for determining the efficacy of anthracycline‑based chemotherapy.